BioForce Nanosciences Holdings Inc. (OTCMKTS:BFNH – Get Free Report) was the recipient of a significant increase in short interest during the month of September. As of September 15th, there was short interest totaling 7,084 shares, an increase of 769.2% from the August 31st total of 815 shares. Based on an average daily volume of 48,995 shares, the short-interest ratio is presently 0.1 days. Currently, 0.0% of the shares of the company are sold short.
BioForce Nanosciences Stock Performance
OTCMKTS BFNH traded down $0.01 on Thursday, reaching $9.19. 4,043 shares of the company’s stock traded hands, compared to its average volume of 8,567. BioForce Nanosciences has a fifty-two week low of $0.18 and a fifty-two week high of $10.99. The firm has a market cap of $349.78 million, a price-to-earnings ratio of 919.80 and a beta of -0.31. The stock has a 50 day moving average price of $4.28 and a 200-day moving average price of $2.12.
BioForce Nanosciences (OTCMKTS:BFNH – Get Free Report) last announced its quarterly earnings results on Monday, August 10th. The company reported $0.01 earnings per share for the quarter.
About BioForce Nanosciences
BioForce Nanosciences is a nanotechnology company that developed instrumentation, consumables and related technologies for life sciences research and nanoscale surface engineering. Its products were designed to help researchers manipulate very small volumes of liquids and create controlled patterns of biological or chemical materials on surfaces.
The company’s best-known technology was the Nano eNabler platform, also described as a molecular printer. The system used specialized dispensing tools to deposit precise quantities of fluids, enabling applications such as biomolecular patterning, microarray fabrication, cell-based research and other laboratory experiments involving nanoscale structures.
BioForce Nanosciences served research institutions, biotechnology companies and other organizations working in nanotechnology and the life sciences.
See Also
- Five stocks we like better than BioForce Nanosciences
- Hims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks
- Paychex Plunges, Providing the Entry Investors Have Been Waiting For
- The Case for Buying High-Yield General Mills Just Strengthened
- SanDisk’s $1,800 Breakout Turns Memory Hardware Into a Profit Story
Receive News & Ratings for BioForce Nanosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioForce Nanosciences and related companies with MarketBeat.com's FREE daily email newsletter.
